Medication Description: Deprenyl
L- (-) N- (1-phenylisopropyl) -N-methyl-N-2-propynylamine.
Synonyms: Selegilin, Yumeks, Selegiline, Eldepryl, Jumex, Tumex.
The chemical structure is similar to ephedrine (see) and other sympathomimetic amines, but it differs in effect in that it is a specific monoamine oxidase (MAO) inhibitor of type B. Other MAO inhibitors, unlike deprenyl, act on MAO type A or have a mixed effect (on MAO type A and B).
The use of deprenil as an antiparkinsonian agent is based on the fact that the content of MAO type B prevails in the brain and inhibition of this enzyme leads to an increase in the concentration of mediator monoamines in brain tissues, including the content of dopamine in the striatum. Especially pronounced increase in the content of dopamine in the neurons of the extrapyramidal system with simultaneous use of deprenyl with L-dof (levodopa). Deprenyl reduces the time of onset of the effect of levodopa and lengthens its action. In this regard, deprenyl with parkinsonism is used in combination with levodopa.
There is evidence that the use of deprenyl in combination with antiparkinsonic drugs in patients with parkinsonism improves lipid metabolism.
Assign deprenyl for 0.005 - 0.01 g (1 - 2 tablets) per day (respectively, 1 tablet in the morning or in the morning and evening). Dose picked individually. At higher doses, the effect is not enhanced. After a few weeks from the start of treatment, you can limit yourself to a lower dose of deprenyl, however, with prolonged treatment, the effectiveness of deprenyl can be reduced.
When using deprenil dose of levodopa can in some cases be reduced.
Deprenyl can be taken in combination with madopar or nakom.
The side effects of treatment with deprenil in combination with levodopa or preparations containing it are similar to those observed with the use of one drug of levodopa, but they may increase.
Deprenyl should not be prescribed for extrapyramidal diseases not related to dopamine deficiency (with essential tremor, Huntington's trochaic, etc.).
Vmpuska form: tablets of 0.005 g (5 mg) and 0.01 g (10 mg) in a package of 10 pieces.
Produced in Hungary.